EMAIL THIS PAGE TO A FRIEND

Psychopharmacology

Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making.


PMID 25529106

Abstract

Despite the evidence for altered decision making in cannabis abusers, the role of the cannabinoid system in decision-making circuits has not been studied. Here, we examined the effects of cannabinoid modulation during cost-benefit decision making in the anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC), key brain areas involved in decision making. We trained different groups of rats in a delay-based and an effort-based form of cost-benefit T-maze decision-making task. During test days, the rats received local injections of either vehicle or ACEA, a cannabinoid type-1 receptor (CB1R) agonist in the ACC or OFC. We measured spontaneous locomotor activity following the same treatments and characterized CB1Rs localization on different neuronal populations within these regions using immunohistochemistry. We showed that CB1R activation in the ACC impaired decision making such that rats were less willing to invest physical effort to gain high reward. Similarly, CB1R activation in the OFC induced impulsive pattern of choice such that rats preferred small immediate rewards to large delayed rewards. Control tasks ensured that the effects were specific for differential cost-benefit tasks. Furthermore, we characterized widespread colocalizations of CB1Rs on GABAergic axonal ends but few colocalizations on glutamatergic, dopaminergic, and serotonergic neuronal ends. These results provide first direct evidence that the cannabinoid system plays a critical role in regulating cost-benefit decision making in the ACC and OFC and implicate cannabinoid modulation of synaptic ends of predominantly interneurons and to a lesser degree other neuronal populations in these two frontal regions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A6226
AM251, >98% (HPLC), solid
C22H21N4OCl2I
SAB2500190
Anti-Cannabinoid receptor 1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
C1108 Anti-Cannabinoid Receptor 1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
C2866 Anti-Cannabinoid Receptor 1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
C1233 Anti-Cannabinoid Receptor 1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
SAB1305934
ANTI-CB1 (CENTER) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2502004
Anti-CNR1 (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502003
Anti-CNR1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405638
Anti-CNR1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4500345
Anti-CNR1 antibody produced in rabbit, affinity isolated antibody
SAB3700370 Anti-Guinea Pig IgG (H+L) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700391 Anti-Guinea Pig IgG (H+L), F(ab′)2 fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700406 Anti-Guinea Pig IgG (H+L), F(ab) fragment antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB3700335 Anti-Guinea Pig IgG F(ab′)2 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB4200039
Anti-Serotonin Transporter (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
SAB2700790
Anti-SLC32A1 (N-terminal) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA058859 Anti-SLC32A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA059985 Anti-SLC32A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2103810
Anti-SLC32A1, (N-terminal) antibody produced in rabbit, affinity isolated antibody
SAB2502144
Anti-SLC6A12 (C-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA034973
Anti-SLC6A12 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2502028
Anti-SLC6A4 (C-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1411290
Anti-SLC6A4 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
V5764 Anti-Vesicular GABA Transporter antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
A9719
Arachidonyl-2′-chloroethylamide hydrate, ≥97% (HPLC), oil
C22H36ClNO · xH2O
WH0001268M1
Monoclonal Anti-CNR1 antibody produced in mouse, clone 2F9, purified immunoglobulin, buffered aqueous solution
SAB1403683
Monoclonal Anti-CNR1, (N-terminal) antibody produced in mouse, clone 1F9, purified immunoglobulin, buffered aqueous solution
WH0006532M6
Monoclonal Anti-SLC6A4 antibody produced in mouse, clone 2A9, purified immunoglobulin, buffered aqueous solution